Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/8810
Full metadata record
DC FieldValueLanguage
dc.contributor.authorEskiyurt, Nurten-
dc.contributor.authorİrdesel, Jale-
dc.contributor.authorSepici, Vesile-
dc.contributor.authorUğurlu, Hatice-
dc.contributor.authorKirazlı, Yeşim-
dc.contributor.authorArdıç, Füsun-
dc.contributor.authorBütün, Bülent-
dc.contributor.authorAkyüz, Gülseren-
dc.contributor.authorCerrahoğlu, Lale-
dc.contributor.authorŞendur, Ömer Faruk-
dc.date.accessioned2019-08-16T12:47:40Z-
dc.date.available2019-08-16T12:47:40Z-
dc.date.issued2012-
dc.identifier.issn2146-3816-
dc.identifier.urihttps://hdl.handle.net/11499/8810-
dc.identifier.urihttps://doi.org/10.4274/tod.29491-
dc.description.abstractAim: BONCURE (Bonviva for Current Bisphosphonate Users Regional European Trial), aimed to evaluate patient preference with monthly ibandronate in women with postmenopausal osteoporosis who previously received daily or weekly alendronate or risendronate. Materials and Methods: This prospective, open-label study consisted of two sequential stages, Part A (screening) and Part B (treatment). Patients enrolled into Part A completed the Candidate Identification Questionnaire (CIQ). In Part B, after completing the Osteoporosis Patient Satisfaction Questionnaire (OPSAT-Q), patients received monthly oral ibandronate 150 mg for 6 months. Following treatment, patients completed the OPSAT-Q and Preference Questionnaire. Results: A total of 223 patients (mean age, 63.7±9.51 years) were enrolled in Part A from Turkey. Among them, 103 (46.2%) answered "YES" to at leastone CIQ question. The mean composite OPSAT-Q domain scores increased for convenience (mean change, 15.3±17.7 points), quality of life (10.4±20.4points), overall satisfaction (11.9±22.7 points), and side effects (3.3±18.8 points). At month 6, 177 subjects (92.7%) preferred once-monthly dosing scheduleand 99.0% were compliant (?80%) with study treatment. Thirty (15.6%) subjects experienced mild to moderate adverse events, mostly gastrointestinal. Conclusion: Postmenopausal women with osteoporosis prefer and are more satisfied and compliant with monthly dosing of ibandronate than daily or weekly bisphosphonate treatment.en_US
dc.language.isoenen_US
dc.publisherGalenos Yayincilik,en_US
dc.relation.ispartofTurk Osteoporoz Dergisien_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBisphosphonateen_US
dc.subjectIbandronateen_US
dc.subjectPatient preferenceen_US
dc.subjectPostmenopausal osteoporosisen_US
dc.subjectalendronic aciden_US
dc.subjectangiotensin II antagonisten_US
dc.subjectanilideen_US
dc.subjectbeta adrenergic receptor blocking agenten_US
dc.subjectcalciumen_US
dc.subjectdihydropyridine derivativeen_US
dc.subjectdipeptidyl carboxypeptidase inhibitoren_US
dc.subjectdiuretic agenten_US
dc.subjecthydroxymethylglutaryl coenzyme A reductase inhibitoren_US
dc.subjectibandronic aciden_US
dc.subjectrisedronic aciden_US
dc.subjectsalicylic aciden_US
dc.subjectsalicylic acid derivativeen_US
dc.subjectserotonin uptake inhibitoren_US
dc.subjectvitamin Den_US
dc.subjectvitamin D derivativeen_US
dc.subjectabdominal painen_US
dc.subjectadulten_US
dc.subjectageden_US
dc.subjectarticleen_US
dc.subjectCandidate Identification Questionnaireen_US
dc.subjectconnective tissue diseaseen_US
dc.subjectdrug efficacyen_US
dc.subjectdrug intoxicationen_US
dc.subjectdrug safetyen_US
dc.subjectdrug substitutionen_US
dc.subjectdrug tolerabilityen_US
dc.subjectdrug withdrawalen_US
dc.subjectdyspepsiaen_US
dc.subjectfemaleen_US
dc.subjectgastrointestinal diseaseen_US
dc.subjectgastrointestinal symptomen_US
dc.subjectherniaen_US
dc.subjecthumanen_US
dc.subjectinfectionen_US
dc.subjectinfestationen_US
dc.subjectinjuryen_US
dc.subjectlung embolismen_US
dc.subjectmajor clinical studyen_US
dc.subjectmetabolic disorderen_US
dc.subjectmulticenter studyen_US
dc.subjectmusculoskeletal diseaseen_US
dc.subjectnauseaen_US
dc.subjectnutritional disorderen_US
dc.subjectopen studyen_US
dc.subjectOsteoporosis Patient Satisfaction Questionnaireen_US
dc.subjectpatient complianceen_US
dc.subjectpatient preferenceen_US
dc.subjectpatient satisfactionen_US
dc.subjectpostmenopause osteoporosisen_US
dc.subjectprospective studyen_US
dc.subjectquality of lifeen_US
dc.subjectquestionnaireen_US
dc.subjectscoring systemen_US
dc.subjectscreening testen_US
dc.subjectstomach upseten_US
dc.subjecttreatment durationen_US
dc.subjecttreatment outcomeen_US
dc.subjectTurkey (republic)en_US
dc.titleOpen, prospective, multi-center, two-part study of patient preference with monthly ibandronate therapy in women with postmenopausal osteoporosis switched from daily or weekly alendronate or risendronate-BONCURE: Results of Turkish sub-studyen_US
dc.typeArticleen_US
dc.identifier.volume18en_US
dc.identifier.issue1en_US
dc.identifier.startpage1en_US
dc.identifier.endpage7en_US
dc.authorid0000-0002-4708-9378-
dc.identifier.doi10.4274/tod.29491-
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.scopus2-s2.0-84862867513en_US
dc.identifier.trdizinid133730en_US
dc.identifier.trdizinid133730en_US
dc.identifier.wosWOS:000409914100001en_US
dc.identifier.scopusqualityQ3-
dc.ownerPamukkale University-
item.cerifentitytypePublications-
item.languageiso639-1en-
item.grantfulltextopen-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextWith Fulltext-
item.openairetypeArticle-
crisitem.author.dept14.02. Internal Medicine-
Appears in Collections:Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
TR Dizin İndeksli Yayınlar Koleksiyonu / TR Dizin Indexed Publications Collection
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection
Files in This Item:
File SizeFormat 
aeaa33cc-5274-4071-8353-c63113733bff.pdf593.14 kBAdobe PDFView/Open
Show simple item record



CORE Recommender

SCOPUSTM   
Citations

1
checked on Nov 16, 2024

WEB OF SCIENCETM
Citations

1
checked on Nov 21, 2024

Page view(s)

46
checked on Aug 24, 2024

Download(s)

22
checked on Aug 24, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.